FindTrial
Sign In

The significance of sustained elevation of plasma GDF-15 in the diagnosis and prognosis of ICU-acquired weakness in mechanically ventilated patients

The significance of sustained elevation of plasma GDF-15 in the diagnosis and prognosis of ICU-acquired weakness in mechanically ventilated patients

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1900025382
Enrollment
Unknown
Registered
2019-08-25
Start date
2019-09-01
Completion date
Unknown
Last updated
2019-08-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ICU-acquired weakness

Interventions

Gold Standard:clinical outcomes
Index test:plasma&#32
growth&#32
differentiation&#32
factor-15&#32
(GDF-15)

Sponsors

The First People's Hospital of Lianyungang City
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 79 Years

Inclusion criteria

Inclusion criteria: Aged >= 18 years; Glasgow Coma Scale (GCS) >= 12; invasive mechanical ventilation treatment; estimated mechanical ventilation treatment for more than 5 days; ICU length of stay >= 7 days.

Exclusion criteria

Exclusion criteria: Unconscious patients, unable to cooperate with the examination; spinal cord injury; acute stroke; lower limb fracture; history of cognitive dysfunction or neuromuscular disease; receiving muscle relaxant treatment; acute and chronic heart failure; acute myocardial infarction.

Design outcomes

Primary

MeasureTime frame
growth differentiation factor-15;SEN, SPE, ACC, AUC of ROC;—

Countries

China

Contacts

Public ContactYongpeng Xie

The First People's Hospital of Lianyungang City

18961325327@163.com+86 18961325327

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026